# Sources — Sun Yat-sen

> **SYNTHETIC RECORD, NOT A REAL MEDICAL RECORD**

Accessed November 4, 2026. The canonical source metadata and claim links are in `case.json`.

## Historical evidence

1. Barth RF, Chen J. “What did Sun Yat-sen really die of? A re-assessment of his illness and the cause of his death.” *Chinese Journal of Cancer* 2016;35(1):81 (PMID 27586157; PMC5009495). Supports his birth on November 12, 1866, and death in Beijing on March 12, 1925; that several months before his operation a mass had been noted in the right upper abdomen and thought to be the liver, growing shortly before surgery; the preoperative findings of no jaundice and not much loss of weight; the exploratory laparotomy at the Peking Union Medical College Hospital on January 26, 1925, by Adrian S. Taylor, which found extensive involvement of the liver by carcinoma; radium treatment for the rest of the stay; his departure against advice on February 18, 1925, and treatment by old-style Chinese doctors; and the limited autopsy of March 13, 1925, by James R. Cash, reporting adenocarcinoma of the gallbladder with obstruction of the cystic duct, direct extension to the liver and diaphragm, metastases to the lungs, peritoneum, ileum and colon, healed cholecystitis, gallstones, generalized arteriosclerosis, healed calcified pulmonary tuberculosis, emphysema, ascites and ascariasis. The authors conclude that the long-held belief in liver cancer came from the laparotomy observations. https://pmc.ncbi.nlm.nih.gov/articles/PMC5009495/
2. Museum of Dr. Sun Yat-sen (Cuiheng). Introduction and biography pages. Support his birth on November 12, 1866, into an ordinary farming family in Cuiheng Village; his childhood name Dixiang and the names Mingwen, Deming, Rixin and Yat-sen; private school at nine, Honolulu at thirteen, return at seventeen; medical study in Guangzhou and Hong Kong from 1886 to 1892 and practice in Macau and Guangzhou; the China Revival Society in Honolulu (1894); the Chinese Revolutionary League in Tokyo (1905); the provisional presidency in Nanjing on New Year’s Day 1912; the invitation to Beijing after the Beijing Coup in the autumn of 1924; and that he “died of liver cancer in Beijing” on March 12, 1925. https://sunyat-sen.org/index.php/portal/list/index.html?id=226 and https://sunyat-sen.org/index.php/portal/list/index.html?id=224
3. Chow YYN. “From medicine to politics” (Dr Sun Yat-sen Oration). *The Hong Kong Practitioner* 2007;29(7). Supports his study at the Canton Hospital medical school, his entry in 1887 to the College of Medicine for Chinese in Hong Kong as one of its twelve students, his teachers including Patrick Manson, his passing the graduation examination as one of two students in 1892 and receiving his diploma at the first graduation ceremony on July 23, 1892; his practice at the Kiang Wu Hospital in Macau and then a dispensary, his move to Guangzhou in 1893, and his giving up medicine for politics about two years after graduating. https://hkcfp.org.hk/Upload/HK_Practitioner/2007/hkp2007vol29jul/dr_sun_yat_sen_oration.html
4. Museum of Dr. Sun Yat-sen (Cuiheng). Chronology (in Chinese). Supports his entry to the Boji Hospital in Guangzhou to study Western medicine in 1886, his transfer in 1887 to the Hong Kong College of Medicine for Chinese, his practice in Macau, Shiqi and Guangzhou with pharmacies of Chinese and Western medicine, his presiding over the First National Congress of the Kuomintang in Guangzhou in January 1924, and his death in Beijing on March 12, 1925. https://sunyat-sen.org/index.php/portal/list/index.html?id=18
5. Tianjin University. “Liu Ruiheng.” Supports that he came to Beijing in poor health on the last day of 1924 and was hospitalized at the Peking Union Medical College Hospital on January 26, 1925, too ill to eat. https://en.tju.edu.cn/info/1073/1295.htm
6. HISTMED Master Roster v3. Internal project source; its entries were not treated as independent corroboration.

## Clinical guidance

1. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Biliary Tract Cancers (2026). Work-up of a gallbladder mass, staging laparoscopy before resection, extended cholecystectomy with liver resection and lymphadenectomy for resectable disease, gemcitabine and cisplatin with durvalumab as a preferred first-line regimen for unresectable or metastatic disease, comprehensive molecular profiling, imaging every 2 to 3 months on treatment. https://www.nccn.org/guidelines/guidelines-detail?category=1&id=1517
2. Singal AG, et al. AASLD Practice Guidance on prevention, diagnosis, and treatment of hepatocellular carcinoma. *Hepatology* 2023 (PMID 37199193). Multiphase CT or MRI for a liver mass; imaging criteria apply only to patients at high risk (cirrhosis or chronic hepatitis B), and biopsy otherwise; assessment of liver function by Child-Pugh and ALBI. https://pubmed.ncbi.nlm.nih.gov/37199193/
3. Oh DY, et al. Durvalumab plus Gemcitabine and Cisplatin in Advanced Biliary Tract Cancer (TOPAZ-1). *NEJM Evidence* 2022 (PMID 38319896). Doses and schedule: gemcitabine 1,000 mg/m2 and cisplatin 25 mg/m2 on days 1 and 8 with durvalumab 1,500 mg every 3 weeks for up to 8 cycles, then durvalumab every 4 weeks. https://pubmed.ncbi.nlm.nih.gov/38319896/
4. Hwang JP, et al. Hepatitis B Virus Screening and Management for Patients With Cancer Prior to Therapy: ASCO Provisional Clinical Opinion Update. *J Clin Oncol* 2020 (PMID 32716741). Screening with surface antigen, core antibody and surface antibody before systemic therapy; for resolved infection outside the highest-risk therapies, monitoring HBV DNA and ALT every 3 months with on-demand antiviral therapy. https://pubmed.ncbi.nlm.nih.gov/32716741/
5. Ferrell BR, et al. Integration of Palliative Care Into Standard Oncology Care: ASCO Clinical Practice Guideline Update. *J Clin Oncol* 2017 (PMID 28034065). Specialist palliative care early in the course of advanced cancer, alongside active treatment. https://pubmed.ncbi.nlm.nih.gov/28034065/
6. Schneider BJ, et al. Management of Immune-Related Adverse Events in Patients Treated With Immune Checkpoint Inhibitor Therapy: ASCO Guideline Update. *J Clin Oncol* 2021 (PMID 34724392). Baseline and periodic TSH, glucose and liver tests; symptom review for immune-related adverse events. https://pubmed.ncbi.nlm.nih.gov/34724392/
7. Taplitz RA, et al. Outpatient Management of Fever and Neutropenia in Adults Treated for Malignancy: ASCO and IDSA Clinical Practice Guideline Update. *J Clin Oncol* 2018 (PMID 29461916). https://pubmed.ncbi.nlm.nih.gov/29461916/
8. U.S. Preventive Services Task Force: colorectal cancer (2021), prostate cancer (2018), depression (2023), unhealthy alcohol use (2018), HIV (2019), hepatitis C (2020), and the A and B recommendations. https://www.uspreventiveservicestaskforce.org/uspstf/recommendation-topics/uspstf-a-and-b-recommendations
9. Centers for Disease Control and Prevention. Adult Immunization Schedule by Medical Condition and Other Indication. https://www.cdc.gov/vaccines/hcp/imz-schedules/adult-medical-condition.html
10. Medicare Preventive Services reference (Aether Forge, 2026). https://patrickrutledge.github.io/preventative_services/

The CMID (Aether Forge) has no monograph for biliary tract or liver cancer, so it is not cited; the specialty guidelines above are used instead.

## Editorial resolutions

- **Recent-death rule.** He died in 1925, so the rule does not apply. Every historical claim is limited to what the fetched sources state.
- **Name.** The record uses “Sun Yat-sen” throughout and “Mr. Sun” in the notes, with the family name first as in Chinese usage. The aliases “Sun Zhongshan” and “Sun Yixian” are the Mandarin romanizations of his best-known names (the museum’s own name is 孙中山故居纪念馆), and “Sun Wen” is his formal given name; none appears in any other record. The museum’s other names for him (Dixiang, Mingwen, Deming, Rixin) are recorded in CLM-0001 only. The project’s FHIR and C-CDA generators split a display name at its last space, so the coded patient name reads given “Sun”, family “Yat-sen”; this is a generator limitation, reported for the owner, and the display name is correct.
- **Index age and dates.** Every visit must fall on or before November 1, 2026. With the true month and day kept, a synthetic date of birth of November 12, 1968 (shift 102 years) maps that cutoff to November 1, 1924, eleven days before his 58th birthday, so the index age is 57, not 58. A shift of 101 years would have placed every visit after his death. The index visit on May 4, 2026 maps to May 4, 1924; the visits on May 18, June 1, August 3 and October 26, 2026, the sick visit on September 2, 2026, and the preventive visit on September 21, 2026 map to the same days of 1924, and the procedures (CT, MRI, biopsy, tumor boards, staging laparoscopy, restaging CTs) between May 7 and October 22 map to 1924 as well. All fall in his lifetime, before his journey north in late 1924 and before the January 26 to February 18, 1925 hospital stay, so nothing contradicts the documented admission. The modern episode therefore places the diagnosis about eight months before the documented operation; this timing is synthetic. Because he is 57, the wellness visit is a periodic adult preventive visit (preventive_adult).
- **The diagnosis and its conflict.** Two accounts are recorded as R claims. CLM-0010 (disputed): his illness was long called liver cancer, as the museum still states, from the findings at the laparotomy. CLM-0011 (probable): the autopsy report, as summarized by Barth and Chen, describes adenocarcinoma of the gallbladder extending into the liver, and they conclude this was the cause of death. The modern diagnosis is chosen to fit both documented findings without asserting more: a gallbladder adenocarcinoma that invades the liver and presents as a liver mass (C23), with peritoneal metastases (C78.6, anchored to the peritoneal metastases at autopsy). The teaching episode mirrors the historical conflict: the mass first looks like a liver tumor, and biopsy and imaging show the gallbladder primary. The AASLD 2023 guidance is cited only for the liver-mass work-up; the NCCN biliary tract cancers guideline governs treatment, so the consultant is a medical oncologist. Histology, immunostains, stage, tumor markers, genomic results and responses are synthetic.
- **Presenting problem.** A right upper quadrant mass with weight loss (R19.01) is the presenting problem at intake, resolved at the consultation on May 18, 2026, when the biopsy diagnosis was recorded. It is anchored to the documented right upper abdominal mass (CLM-0007), whose start is not dated beyond “several months” before January 1925. The intake documents state only what was known then; the staging and hepatitis B monitoring plans are dated to the consultation, chemoimmunotherapy and palliative care to the visit after the staging laparoscopy, and magnesium replacement and maintenance to the last visit.
- **Hepatitis B.** No fetched source mentions hepatitis. The modern serology (resolved infection, HBV DNA undetectable) is synthetic and chosen for its teaching value in a patient starting chemotherapy and immunotherapy; it is not a claim about his real health. PRB-003 has no historical claim link.
- **Autopsy findings used as anchors.** The gallstones and the 6 mm calcified lung granuloma in the modern imaging echo the gallstones and healed calcified tuberculosis at autopsy (CLM-0011); they are synthetic findings. The autopsy’s emphysema, arteriosclerosis, ascites and ascariasis are not modeled. No past medical history is recorded, because no fetched source dates an illness before the true-frame index date.
- **Physician as patient.** His documented medical training and brief practice (CLM-0003, CLM-0004) anchor the theme: he asks to see his images, wants plain information and asks to be cared for on the standard pathway, and the clinicians share results in full while keeping to the same thresholds as for any patient. His modern work as the leader of a political organization is synthetic, anchored to CLM-0005.
- **Real people.** His wives appear in no claim; his modern wife is unnamed and has no role, and his health care agent is not named. Adrian S. Taylor, James R. Cash and Liu Ruiheng appear only in the documented history. No modern decision, statement or health fact is attributed to any real person.
- **Death.** Barth and Chen state that he moved from the hospital to the Kuomintang headquarters, the former Wellington Koo residence, before he died; secondary web pages that place his death at the hospital were not used. CLM-0009 records only that he died in Beijing on March 12, 1925.
- **Sick visit.** A same-day visit for a cold (J06.9) on day 10 of cycle 5, chosen because it is common, insinuates no undocumented real diagnosis, and interacts with his treatment: mild neutropenia without fever (not febrile neutropenia), pneumonitis from durvalumab weighed and judged unlikely, no antibiotics, and fever precautions.
- **Preventive visit.** A periodic adult preventive visit at age 57 (CPT 99396 and 99497 in plain text), adjusted to metastatic cancer: inactivated influenza, COVID-19 and PCV20 vaccines (immunosuppression by chemotherapy), recombinant zoster vaccine planned for the next visit and given there, an HIV test (negative), colorectal and prostate screening not offered after discussion because their benefit would not be realized, and advance care planning with an unnamed agent.
- **Focused visits.** The four chronic-care follow-ups (the consultation day, the start of treatment, before cycle 4, and before cycle 8) are documented as focused visits on the NCCN biliary tract cancers guideline, TOPAZ-1, the AASLD 2023 guidance (work-up only), and the ASCO hepatitis B, immune-related adverse event and palliative care guidelines. Two protocol deviations are recorded at the first treatment visit: (1) glucose was not on the cycle 1 day 1 panel, a baseline the ASCO guideline expects before immunotherapy; intake glucose was 98 mg/dL and he had no symptoms, no harm is apparent, and glucose was added to the standing order (94 and 96 mg/dL at the next two visits); (2) no baseline audiogram before cisplatin; he had no hearing symptoms at any visit, and the corrective action was symptom review each cycle with an audiogram for any change. Pre-dose blood tests at infusion visits outside this clinic’s encounters are not recorded as results.
- **Consultation.** The medical oncology referral and the consultation by Raymond Choi, MD (a fictional consultant), on the day of the biopsy result, are **S**. The consultant answers the five referral questions in line with what the record shows afterwards: a gallbladder primary rather than a liver cancer; staging laparoscopy (peritoneal metastases found); preserved liver function and hepatitis B monitoring rather than prophylaxis (HBV DNA stayed undetectable); gemcitabine, cisplatin and durvalumab for metastatic disease (started at the next visit); genomic profiling (no targetable alteration); palliative care once advanced disease was confirmed (started at the next visit); and plain, complete communication.
- **Synthetic content.** All visits, laboratory values, imaging, pathology, genomic results, vital signs, PHQ-2, PHQ-9 and ECOG scores, medicines and doses, his height (165 cm), and his modern household are synthetic. Qualitative results (biopsy and peritoneal pathology, immunostains, imaging reports, hepatitis serology, HBV DNA, SARS-CoV-2 and influenza tests, the HIV test, genomic profiling) appear only in the note text.
- **Not verified, not used.** The hospital’s original case notes and slides, any account of the radium dose, the identity of the old-style Chinese doctors, and accounts of a stolen autopsy report or specimens (found only on secondary web pages) were not fetched and are not used. The British-era Hong Kong government’s non-recognition of his diploma is mentioned by one source and is not used.
